Therapeutically, FDA-approved inhibitors ivosidenib (IDH1) and enasidenib (IDH2) reduce D-2HG levels, restore differentiation, and enhance anti-tumor immunity in AML, demonstrating clinical efficacy [70, 71]. This evidence concerns the gene IDH1 and acute myeloid leukemia.